

1 ENGROSSED SENATE  
2 BILL NO. 1344

By: Rosino of the Senate

and

West (Josh) and Munson of  
the House

3  
4  
5  
6  
7 An Act relating to nonopioid alternatives; directing  
8 specified agencies to seek certain funding  
9 opportunities and provide certain assistance with  
10 opioid grant awards; defining term; granting certain  
11 protection to nonopioid drugs relating to Medicaid  
12 drug formulary; prohibiting certain denial of  
13 coverage; providing certain construction; amending 74  
14 O.S. 2021, Section 30.5, as amended by Section 1,  
15 Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2023, Section  
16 30.5), which relates to definitions used in the  
17 Political Subdivisions Opioid Abatement Grants Act;  
18 broadening approved purposes; providing for  
19 codification; and providing an effective date.

20  
21  
22 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

23 SECTION 1. NEW LAW A new section of law to be codified  
24 in the Oklahoma Statutes as Section 2-402 of Title 43A, unless there  
is created a duplication in numbering, reads as follows:

The Department of Mental Health and Substance Abuse Services,  
the State Department of Health, and the Oklahoma Health Care  
Authority shall:

1. Collaborate to seek funding opportunities for educational  
and health care services related to nonopioid alternatives; and

1           2. Assist, upon request, political subdivisions that receive  
2 opioid grant awards under the Political Subdivisions Opioid  
3 Abatement Grants Act with the development and implementation of  
4 educational and health care services related to nonopioid  
5 alternatives.

6           SECTION 2.           NEW LAW           A new section of law to be codified  
7 in the Oklahoma Statutes as Section 5031 of Title 63, unless there  
8 is created a duplication in numbering, reads as follows:

9           A. As used in this section, "contracted entity" has the same  
10 meaning as provided by Section 4002.2 of Title 56 of the Oklahoma  
11 Statutes.

12           B. In establishing and maintaining the formulary for the state  
13 Medicaid program, the Oklahoma Health Care Authority shall ensure  
14 that no nonopioid drug approved by the United States Food and Drug  
15 Administration (FDA) for the treatment or management of pain shall  
16 be disadvantaged or discouraged by either the Authority or a  
17 contracted entity with respect to coverage on the formulary relative  
18 to any opioid or narcotic drug for the treatment or management of  
19 pain.

20           C. When a contracted provider prescribes an FDA-approved  
21 nonopioid drug for the treatment or management of pain, the  
22 Authority or a contracted entity shall not deny coverage of the  
23 nonopioid drug in favor of an opioid drug.

24

1 D. This section does not preclude opioid drugs from being  
2 preferred over other opioid drugs or nonopioid drugs from being  
3 preferred over other nonopioid drugs.

4 SECTION 3. AMENDATORY 74 O.S. 2021, Section 30.5, as  
5 amended by Section 1, Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2023,  
6 Section 30.5), is amended to read as follows:

7 Section 30.5. As used in the Political Subdivisions Opioid  
8 Abatement Grants Act:

- 9 1. "Approved purpose" and "approved purposes" mean evidence-  
10 based, forward-looking strategies, programming and services used to:
- 11 a. expand the availability of treatment for individuals  
12 affected by opioid use disorders, co-occurring  
13 substance use disorders and mental health issues,
  - 14 b. develop, promote and provide evidence-based opioid use  
15 prevention strategies,
  - 16 c. provide opioid use disorder and co-occurring substance  
17 use disorder avoidance and awareness education,
  - 18 d. decrease the oversupply of licit and illicit opioids,
  - 19 e. support recovery from addiction services performed by  
20 qualified and appropriately licensed providers,
  - 21 f. treat opioid use, abuse and disorders including early  
22 intervention screening, counseling and support,
  - 23 g. support individuals in treatment and recovery from  
24 opioid use, abuse and disorder,

- 1           h.    provide programs or services to connect individuals  
2           with opioid use, abuse or disorder, or who are at risk  
3           of developing opioid use disorder, co-occurring  
4           substance use disorder and mental health issues, with  
5           treatment and counseling programs and services,
- 6           i.    address the needs of individuals who are involved, or  
7           who are at risk of becoming involved, in the criminal  
8           justice system due to opioid use, abuse or disorder  
9           through programs or services in municipal and county  
10          criminal judicial systems including prearrest and  
11          postarrest diversion programs, pretrial services and  
12          drug or recovery courts,
- 13          j.    address the needs of pregnant or parenting women with  
14          opioid use, abuse or disorder and their families,
- 15          k.    address the needs of parents and caregivers caring for  
16          babies with neonatal abstinence syndrome,
- 17          l.    support efforts to prevent overprescribing and ensure  
18          appropriate prescribing and dispensing of opioids,
- 19          m.    support efforts to discourage or prevent misuse of  
20          opioids including the oversupply of licit and illicit  
21          opioids,
- 22          n.    support efforts to prevent or reduce overdose deaths  
23          or other opioid-related harms including through  
24          increased availability and distribution of naloxone

1 and other drugs that treat overdoses for use by first  
2 responders, persons who have experienced an overdose  
3 event, families, schools, community-based service  
4 providers, social workers and other members of the  
5 public,

6 o. reimburse or fund law enforcement and emergency  
7 responder expenditures relating to the opioid epidemic  
8 including costs of responding to emergency medical or  
9 police calls for service, equipment, treatment or  
10 response alternatives, mental health response training  
11 and training for law enforcement and emergency  
12 responders as to appropriate practices and precautions  
13 when dealing with opioids or individuals who are at  
14 risk of opioid overdose or death,

15 p. reimburse attorney fees and allowable expenses  
16 directly related to opioid litigation incurred as part  
17 of legal services agreements entered into before May  
18 21, 2020,

19 q. support efforts to provide leadership, planning and  
20 coordination to abate the opioid epidemic through  
21 activities, programs or strategies for prevention and  
22 recovery models including regional intergovernmental  
23 efforts and not-for-profit agency support,  
24

- 1           r.    support education of youths regarding the dangers of  
2                    opioid use, abuse and addiction,  
3           s.    fund training relative to any approved purpose,  
4           t.    monitor, surveil and evaluate opioid use, abuse or  
5                    disorder, ~~or~~  
6           u.    provide educational and health care services related  
7                    to nonopioid treatment alternatives, or  
8           v.   provide opioid abatement as identified by the Oklahoma  
9                    Opioid Abatement Board as consistent with the purpose  
10                   of the Political Subdivisions Opioid Abatement Grants  
11                   Act.

12   Provided that, such strategies, programming and services occurred on  
13   or after January 1, 2015;

14         2.    "Board" means the Oklahoma Opioid Abatement Board;

15         3.    "Eligible participant" means any political subdivision  
16   impacted by the opioid crisis;

17         4.    "Nonapproved purpose" and "nonapproved purposes" mean  
18   strategies, programming and services not falling within the  
19   definition of approved purpose or approved purposes as defined in  
20   this section;

21         5.    "Opioid funds" means all monetary amounts obtained through a  
22   settlement or judgment by the Attorney General on behalf of this  
23   state related to opioid litigation involving pharmaceutical supply  
24   chain participants including the Purdue Political Subdivisions Fund

1 but excluding all other funds received pursuant to the Purdue  
2 Settlement Agreement;

3 6. "Opioid grant awards" means grants funded from the Oklahoma  
4 Opioid Abatement Revolving Fund, awarded pursuant to the provisions  
5 of the Political Subdivisions Opioid Abatement Grants Act;

6 7. "Pharmaceutical supply chain" means the process and channels  
7 through which controlled substances are manufactured, marketed,  
8 promoted, distributed or dispensed;

9 8. "Pharmaceutical supply chain participant" means any entity  
10 that engages in or has engaged in the manufacture, marketing,  
11 promotion, distribution or dispensing of an opioid analgesic;

12 9. "Political subdivision" and "political subdivisions" have  
13 the same meaning as provided in subparagraphs a, b, c and d of  
14 paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes;

15 10. "Purdue Political Subdivision Fund" means the Twelve  
16 Million Five Hundred Thousand Dollars (\$12,500,000.00) plus any  
17 interest accrued thereon received from the Revive Oklahoma Health  
18 Foundation consisting of funds from the Purdue Settlement Agreement  
19 designed for distribution to political subdivisions which have  
20 executed a release of legal claims as required by the Purdue  
21 Settlement Agreement; and

22 11. "Purdue Settlement Agreement" means the settlement  
23 agreement entered into by this state and Purdue Pharma L.P., Purdue  
24

1 Pharma, Inc. and the Purdue Frederick Company on March 26, 2019, and  
2 approved by the Court on April 2, 2019.

3 SECTION 4. This act shall become effective November 1, 2024.

4 Passed the Senate the 14th day of March, 2024.

5

6

\_\_\_\_\_  
Presiding Officer of the Senate

7

8 Passed the House of Representatives the \_\_\_\_ day of \_\_\_\_\_,

9 2024.

10

11

\_\_\_\_\_  
Presiding Officer of the House  
of Representatives

12

13

14

15

16

17

18

19

20

21

22

23

24